First Patient Dosed in FDA-Approved Phase III Lenzilumab Study for COVID-19

Burlingame, CA, May 6, 2020 – Humanigen, Inc., (HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the company’s proprietary...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials